Emory University’s BioCryst Pharmaceuticals BCRX Stock Holding History

Emory University’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-479,902	Closed	-$1.38M	–	5
2019 Q3	$1.38M	Sell	479,902 -165,681	-26%	-$515K	2.71%	7
2019 Q2	$2.45M	Buy	645,583 +380,570	+144%	+$2.29M	1.72%	16
2019 Q1	$2.16M	Sell	265,013 -52,732	-17%	-$451K	1.52%	29
2018 Q4	$2.56M	Buy	+317,745	New	+$2.47M	2.02%	7
2018 Q1	–	Sell	-383,768	Closed	-$1.88M	–	48
2017 Q4	$1.88M	Buy	383,768 +23,726	+7%	+$115K	1.62%	25
2017 Q3	$1.89M	Buy	360,042 +72,492	+25%	+$371K	1.49%	14
2017 Q2	$1.6M	Sell	287,550 -87,798	-23%	-$535K	1.41%	29
2017 Q1	$3.15M	Buy	+375,348	New	+$2.61M	2.98%	2
2015 Q3	$1.48M	Buy	+129,415	New	+$1.73M	4.11%	5
2015 Q2	–	Sell	-98,161	Closed	-$886K	–	22
2015 Q1	$886K	Buy	+98,161	New	+$1.02M	1.68%	10

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Emory University's BCRX Position: Q4 2019 in Review

Emory University sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2019, closing a stake of 479,902 shares — an estimated $1.38M sold.

Emory University first reported a position in BCRX in Q1 2015 and held it in 10 quarters. The position peaked at $3.15M in Q1 2017. 136 funds tracked by Wall St. Rank hold BCRX as of Q4 2019.

Emory University reported no remaining BioCryst Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Emory University sold 479,902 BioCryst Pharmaceuticals shares in Q4 2019, an estimated $1.38M.
Emory University first reported a position in BioCryst Pharmaceuticals in Q1 2015 and held it in 10 quarters.
Emory University's BioCryst Pharmaceuticals position peaked at $3.15M in Q1 2017.
136 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2019.

Based on Emory University's 13F filing for Q4 2019, filed 13 Feb 2020.